Literature DB >> 19221213

Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study.

Joanna Matrozova1, Olivier Steichen, Laurence Amar, Sabina Zacharieva, Xavier Jeunemaitre, Pierre-François Plouin.   

Abstract

An association between primary aldosteronism and metabolism disorders has been reported. The aim of this retrospective study was to test for this association by comparison between large cohorts of patients with primary aldosteronism and with essential hypertension. We retrieved the records of 460 cases with primary aldosteronism (103 lateralized, 150 not lateralized, and 207 undetermined) and of 1363 controls with essential hypertension individually matched for age and sex. We compared clinical history; blood pressure levels; body mass index; levels of fasting plasma glucose and serum triglycerides; total, high-density lipoprotein, and low-density lipoprotein cholesterol; and the prevalence of diabetes mellitus and impaired fasting glucose among subtypes of primary aldosteronism, as well as between cases with primary aldosteronism and their matched controls. Fasting plasma glucose and serum lipid levels did not differ among the 3 subtypes of primary aldosteronism. The prevalence of impaired fasting glucose was lower in patients with primary aldosteronism than their matched controls, but the prevalence of hyperglycemia (impaired fasting glucose or diabetes mellitus) and blood levels of glucose and lipids did not differ between cases and controls. There was no significant difference between preoperative and postoperative levels of either fasting plasma glucose or serum lipids in patients who underwent adrenalectomy and had follow-up data available. The analysis of this large group of patients with primary aldosteronism and essential hypertension does not confirm a higher prevalence of carbohydrate or lipid metabolism disorders in the former. It is unlikely that the prevalence of metabolic syndrome differs significantly between patients with primary aldosteronism and those with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221213     DOI: 10.1161/HYPERTENSIONAHA.108.122002

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  29 in total

1.  Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease.

Authors:  Wei-Guo Chen; Ting-Ting Zhou; Peng Zhou; Xiao-Wei Li; Zhun Wu; Kai-Yan Zhang; Jin-Chun Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 2.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

Review 3.  Aldosterone and cardiovascular risk.

Authors:  Bruno Vogt; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

4.  Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans.

Authors:  James M Luther; Loretta M Byrne; Chang Yu; Thomas J Wang; Nancy J Brown
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

Review 5.  Mineralocorticoid receptor antagonists and the metabolic syndrome.

Authors:  Amir Tirosh; Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

6.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

Review 7.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

8.  The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.

Authors:  Chin-Chi Kuo; Poojitha Balakrishnan; Yenh-Chen Hsein; Vin-Cent Wu; Shih-Chieh Jeff Chueh; Yung-Ming Chen; Kwan-Dun Wu; Ming-Jiuh Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-07-16       Impact factor: 1.636

9.  Abnormal aldosterone physiology and cardiometabolic risk factors.

Authors:  Anand Vaidya; Patricia C Underwood; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Gordon H Williams; Gail K Adler
Journal:  Hypertension       Date:  2013-02-11       Impact factor: 10.190

Review 10.  Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?

Authors:  Huai Heng Loh; Norlela Sukor
Journal:  J Hum Hypertens       Date:  2019-12-10       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.